Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) – Research analysts at HC Wainwright upped their Q2 2023 earnings per share (EPS) estimates for Indaptus Therapeutics in a research report issued on Monday, March 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.63) for the quarter, up […]
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 182,100 shares, a growth of 569.5% from the May 15th total of 27,200 shares. Currently, 3.2% of the shares of the stock are short sold. Based on an average daily […]
Analysts predict that Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) will report earnings per share of ($0.43) for the current quarter, Zacks reports. Zero analysts have made estimates for Indaptus Therapeutics’ earnings. Indaptus Therapeutics posted earnings of ($5.53) per share in the same quarter last year, which would suggest a positive year over year growth […]
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 27,200 shares, a drop of 38.3% from the April 30th total of 44,100 shares. Currently, 0.5% of the shares of the company are sold […]